Literature DB >> 20597012

Refinement of the hamster model of Clostridium difficile disease.

Gillian Douce1, David Goulding.   

Abstract

The Golden Syrian hamster is widely regarded as the most relevant small animal model of Clostridium difficile disease as oral infection of animals pre-treated with antibiotics reproduces many of the symptoms observed in man. These include diarrhoea, histological damage, colonisation of the large bowel and sporulation of the organism at the terminal stage of the disease. However, infection results in a fatal outcome, which in the past has been used as an experimental endpoint. More recently, attempts have been made to refine the model to maximise the scientific data generated whilst minimising animal suffering. This has been achieved using a combination of qualitative and quantitative measurements taken during the course of the infection and at post-mortem. This has allowed timing of experiments to be optimised to ensure appropriate monitoring of animals during the acute phase of infection and provides opportunities to establish appropriate humane endpoints to these experiments.

Entities:  

Mesh:

Year:  2010        PMID: 20597012     DOI: 10.1007/978-1-60327-365-7_14

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  19 in total

1.  A novel regulator controls Clostridium difficile sporulation, motility and toxin production.

Authors:  Adrianne N Edwards; Rita Tamayo; Shonna M McBride
Journal:  Mol Microbiol       Date:  2016-03-22       Impact factor: 3.501

2.  Conserved oligopeptide permeases modulate sporulation initiation in Clostridium difficile.

Authors:  Adrianne N Edwards; Kathryn L Nawrocki; Shonna M McBride
Journal:  Infect Immun       Date:  2014-07-28       Impact factor: 3.441

3.  The non-toxigenic Clostridium difficile CD37 protects mice against infection with a BI/NAP1/027 type of C. difficile strain.

Authors:  Keshan Zhang; Song Zhao; Yuankai Wang; Xuejun Zhu; Hong Shen; Yugen Chen; Xingmin Sun
Journal:  Anaerobe       Date:  2015-10-13       Impact factor: 3.331

Review 4.  Models for the study of Clostridium difficile infection.

Authors:  Emma L Best; Jane Freeman; Mark H Wilcox
Journal:  Gut Microbes       Date:  2012-03-01

5.  Markers for predicting death as an outcome for mice used in infectious disease research.

Authors:  Rita A Trammell; Linda A Toth
Journal:  Comp Med       Date:  2011-12       Impact factor: 0.982

6.  Novel riboswitch-binding flavin analog that protects mice against Clostridium difficile infection without inhibiting cecal flora.

Authors:  Kenneth F Blount; Cynthia Megyola; Mark Plummer; David Osterman; Tim O'Connell; Paul Aristoff; Cheryl Quinn; R Alan Chrusciel; Toni J Poel; Heinrich J Schostarez; Catherine A Stewart; Daniel P Walker; Peter G M Wuts; Ronald R Breaker
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

7.  Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.

Authors:  Kasper Krogh Andersen; Nika M Strokappe; Anna Hultberg; Kai Truusalu; Imbi Smidt; Raik-Hiio Mikelsaar; Marika Mikelsaar; Theo Verrips; Lennart Hammarström; Harold Marcotte
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

8.  Isolating and Purifying Clostridium difficile Spores.

Authors:  Adrianne N Edwards; Shonna M McBride
Journal:  Methods Mol Biol       Date:  2016

9.  Effect of the Synthetic Bile Salt Analog CamSA on the Hamster Model of Clostridium difficile Infection.

Authors:  Amber Howerton; Cale O Seymour; Senthil K Murugapiran; Zhenlin Liao; Jacqueline R Phan; Alan Estrada; Adam J Wagner; Chrisabelle C Mefferd; Brian P Hedlund; Ernesto Abel-Santos
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

10.  Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile.

Authors:  Gregory L Peterfreund; Lee E Vandivier; Rohini Sinha; Andre J Marozsan; William C Olson; Jun Zhu; Frederic D Bushman
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.